Repligen Co. (NASDAQ:RGEN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Repligen Co. (NASDAQ:RGEN) have earned a consensus recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $188.38.

A number of brokerages have recently issued reports on RGEN. Stephens restated an “overweight” rating and set a $170.00 price objective on shares of Repligen in a research report on Tuesday, July 30th. Guggenheim assumed coverage on shares of Repligen in a research report on Tuesday, June 18th. They issued a “neutral” rating on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $190.00 price objective on shares of Repligen in a research report on Wednesday, July 31st. JPMorgan Chase & Co. boosted their target price on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 31st. Finally, Benchmark reiterated a “hold” rating on shares of Repligen in a report on Monday, August 5th.

Repligen Stock Performance

NASDAQ:RGEN opened at $139.99 on Monday. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. Repligen has a 1-year low of $110.45 and a 1-year high of $211.13. The stock’s 50-day moving average is $145.43 and its 200-day moving average is $156.84. The stock has a market cap of $7.84 billion, a P/E ratio of 559.98, a price-to-earnings-growth ratio of 4.20 and a beta of 0.94.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, hitting the consensus estimate of $0.33. The company had revenue of $154.07 million for the quarter, compared to analysts’ expectations of $154.11 million. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. Repligen’s revenue for the quarter was down 3.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.53 earnings per share. Equities research analysts anticipate that Repligen will post 1.45 earnings per share for the current year.

Insider Buying and Selling at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Repligen news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the sale, the vice president now owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Repligen

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. CWM LLC lifted its position in shares of Repligen by 19.9% during the 1st quarter. CWM LLC now owns 361 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 60 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Repligen by 0.3% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,178 shares of the biotechnology company’s stock worth $3,805,000 after purchasing an additional 62 shares during the period. Commerce Bank increased its stake in shares of Repligen by 4.5% in the fourth quarter. Commerce Bank now owns 1,683 shares of the biotechnology company’s stock worth $303,000 after purchasing an additional 72 shares in the last quarter. Toronto Dominion Bank raised its position in shares of Repligen by 1.5% in the second quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 75 shares during the period. Finally, Quadrant Capital Group LLC raised its position in shares of Repligen by 15.1% in the fourth quarter. Quadrant Capital Group LLC now owns 649 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 85 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.